Ratings GoHealth, Inc.

Equities

GOCO

US38046W2044

Delayed Nasdaq Other stock markets 10:24:22 2024-04-24 am EDT			5-day change	1st Jan Change
10.01 ^USD	-1.28%		+1.01%	-24.96%

Mar. 20	RBC Cuts Price Target on GoHealth to $13 From $20, Notes 'Diminished Topline Visibility' in Near Term; Sector Perform Kept	MT
Mar. 14	GoHealth Shares Tumble After Surprise Q4 Loss, Revenue Miss	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Multiline Insurance & Brokers

	1st Jan change	Capi.	ESG Refinitiv
GOHEALTH, INC.	-24.96%	98.34M	D+
AON PLC	+6.13%	61.89B	C
ARTHUR J. GALLAGHER & CO.	+4.84%	51.93B	B-
WILLIS TOWERS WATSON PUBLIC LIMITED COMPANY	+9.31%	26.96B	C+
BROWN & BROWN, INC.	+15.08%	23.66B	C
CAIXA SEGURIDADE PARTICIPAÇÕES S.A.	+23.18%	9.09B	-
RYAN SPECIALTY HOLDINGS, INC.	+18.55%	6.06B	-
STEADFAST GROUP LIMITED	-2.58%	4.03B	B
AUB GROUP LIMITED	+3.75%	2.02B	C+
BRP GROUP, INC.	+14.07%	1.81B	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes